American International Group Inc. boosted its stake in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 7.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,843 shares of the biotechnology company’s stock after buying an additional 4,951 shares during the period. American International Group Inc. owned approximately 0.06% of ZIOPHARM Oncology worth $475,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Highbridge Capital Management LLC acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at about $164,000. UBS Asset Management Americas Inc. boosted its position in ZIOPHARM Oncology by 79.6% in the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 16,700 shares during the last quarter. Private Advisor Group LLC boosted its position in ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 7,875 shares during the last quarter. Creative Planning boosted its position in ZIOPHARM Oncology by 289.3% in the first quarter. Creative Planning now owns 57,863 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 43,000 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in ZIOPHARM Oncology by 325.7% in the first quarter. Parametric Portfolio Associates LLC now owns 81,011 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 61,979 shares during the last quarter. 38.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) traded down 4.19% during midday trading on Tuesday, reaching $5.71. The company had a trading volume of 807,449 shares. ZIOPHARM Oncology Inc has a 52-week low of $4.55 and a 52-week high of $7.88. The company’s 50-day moving average is $5.93 and its 200-day moving average is $6.33. The firm’s market cap is $803.01 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. ZIOPHARM Oncology’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.01) EPS. Equities research analysts expect that ZIOPHARM Oncology Inc will post ($0.54) EPS for the current fiscal year.
Several brokerages recently weighed in on ZIOP. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, HC Wainwright began coverage on ZIOPHARM Oncology in a research note on Thursday, June 1st. They set a “buy” rating and a $9.50 target price for the company. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $13.17.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with our FREE daily email newsletter.